Skip to main content
Figure 2 | Journal of Experimental & Clinical Cancer Research

Figure 2

From: Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients

Figure 2

PankoMabGEX™ predicts overall survival in breast cancer. Univariate analysis revealed significant differences regarding overall survival of the four subgroups (mem-PankoMab-GEX™ positive, cyt-PankoMab-GEX™ positive, double negative and double positive) studied (A). mem-PankoMab-GEX™ positivity turned out to be related to more favourable (B) survival, while a double negative immunophenotype was associated with worse prognosis (D). Neither cyt-PankoMab-GEX™ positivity (C) nor a double positive immunophenotype (E) was predictive for overall survival. The term “remaining cases” refers to the three immunophenotypes different from the one indicated in the respective graph (B-E).

Back to article page